Search results for "ldl"

showing 10 items of 664 documents

Chemometric determination of lipidic parameters in serum using ATR measurements of dry films of solvent extracts

2013

Attenuated total reflectance (ATR) infrared spectroscopy of dried organic extracts of serum samples has been evaluated as a fast method for the determination of triglycerides, cholesterol, high density lipoprotein (HDL) and low density lipoprotein (LDL). After careful selection of solvents based on green parameters, serum samples were extracted using hexane-isopropanol and ethyl acetate-ethanol mixtures. Microscopy studies and comparison with standard spectra were performed in order to investigate whether the proposed methodology is suitable for the quantification of lipids in serum samples. The results of these preliminary studies confirmed that the variations in the IR spectra of sample e…

AnalyteChromatographySpectrophotometry InfraredCholesterolCholesterol HDLExtraction (chemistry)Analytical chemistryInfrared spectroscopyCholesterol LDLBiochemistryAnalytical ChemistrySolventchemistry.chemical_compoundchemistryLow-density lipoproteinAttenuated total reflectionSpectroscopy Fourier Transform InfraredPartial least squares regressionSolventsElectrochemistryHumansEnvironmental ChemistryTriglyceridesSpectroscopyThe Analyst
researchProduct

The lipoprotein receptor LRP1 modulates sphingosine-1-phosphate signaling and is essential for vascular development

2014

Low density lipoprotein receptor-related protein 1 (LRP1) is indispensable for embryonic development. Comparing different genetically engineered mouse models, we found that expression of Lrp1 is essential in the embryo proper. Loss of LRP1 leads to lethal vascular defects with lack of proper investment with mural cells of both large and small vessels. We further demonstrate that LRP1 modulates Gi-dependent sphingosine-1-phosphate (S1P) signaling and integrates S1P and PDGF-BB signaling pathways, which are both crucial for mural cell recruitment, via its intracellular domain. Loss of LRP1 leads to a lack of S1P-dependent inhibition of RAC1 and loss of constraint of PDGF-BB-induced cell migra…

AngiogenesisBlotting WesternBecaplerminEmbryonic DevelopmentNeovascularization PhysiologicRAC1BiologyReal-Time Polymerase Chain ReactionMural cellchemistry.chemical_compoundMiceCell MovementSphingosineHuman Umbilical Vein Endothelial CellsAnimalsHumansSphingosine-1-phosphateMolecular BiologyResearch ArticlesIn Situ HybridizationSphingosineTumor Suppressor ProteinsCell migrationCell BiologyProto-Oncogene Proteins c-sisLRP1ImmunohistochemistryCell biologyMicroscopy ElectronchemistryReceptors LDLLow-density lipoproteinSignal transductionLysophospholipidsGenetic EngineeringLow Density Lipoprotein Receptor-Related Protein-1Developmental BiologySignal Transduction
researchProduct

Animal Perception of Seasonal Thresholds: Changes in Elephant Movement in Relation to Rainfall Patterns

2012

Background The identification of temporal thresholds or shifts in animal movement informs ecologists of changes in an animal’s behaviour, which contributes to an understanding of species’ responses in different environments. In African savannas, rainfall, temperature and primary productivity influence the movements of large herbivores and drive changes at different scales. Here, we developed a novel approach to define seasonal shifts in movement behaviour by examining the movements of a highly mobile herbivore (elephant; Loxodonta africana), in relation to local and regional rainfall patterns. Methodology/Principal Findings We used speed to determine movement changes of between 8 and 14 GPS…

Animal TypesRainElephantslcsh:MedicineWildlifeEnvironmentEcosystemsBehavioral EcologySouth Africaseasonal thresholdBehavioral ecologyDry seasonmedicineAnimalsEcosystemSegmented regressionTerrestrial Ecologylcsh:ScienceBiologyEcosystemAnimal ManagementConservation ScienceHerbivoreEvolutionary BiologyMultidisciplinaryAnimal BehaviorEcologyBehavior AnimalNational parkEcologylcsh:RTemperatureAgricultureSeasonalityAutecologymedicine.diseaseGeographyMammalogyEcosystem Engineeringlcsh:Qelephant movementVeterinary ScienceAnimal MigrationFemaleSeasonsScale (map)ZoologyResearch ArticlePLoS ONE
researchProduct

Tiliroside and gnaphaliin inhibit human low density lipoprotein oxidation.

2004

Two flavonoids, gnaphaliin and tiliroside, isolated from Helichrysum italicum, were studied in vitro for their capacity to inhibit Cu(2+)-induced human low density lipoprotein (LDL) and diluted plasma oxidation. LDL oxidation was monitored by conjugated diene, thiobarbituric acid-reactive substances (TBARS) formation and electrophoretic mobility on agarose gel. Gnaphaliin and tiliroside increased the lag-phase for diene conjugate production in a dose-dependent manner. The reduction of TBARS production confirmed the antioxidant activity of gnaphaliin and tiliroside with 50% inhibitory concentration (IC(50)) values of 8.0+/-3.9 microM and 7.0+/-2.6 microM respectively. Furthermore, the flavon…

AntioxidantCopper Sulfatemedicine.medical_treatmentProbucolPharmacognosyThiobarbituric Acid Reactive SubstancesLipid peroxidationchemistry.chemical_compoundInhibitory Concentration 50Drug DiscoverymedicineTBARSHumansBenzopyransIC50PharmacologyFlavonoidsHelichrysumChromatographyPlant ExtractsGeneral MedicineCholesterol LDLPlant Components AerialFlavonesLipoproteins LDLBiochemistrychemistryLow-density lipoproteinAgaroseLipid Peroxidationmedicine.drugPhytotherapyFitoterapia
researchProduct

Glucose and free radicals impair the antioxidant properties of serum albumin

1999

Epidemiological data consistently show that reduced levels of serum albumin, which is the most abundant protein in plasma, are associated with an increased mortality risk. Various biological properties evidenced by direct effects of the albumin molecule may explain its beneficial effects. The present work aimed to investigate in vitro whether glycation or free radicals or both factors would affect the antioxidant properties of bovine serum albumin (BSA). Glycation was performed by long-term incubations (60 days) of BSA with increasing concentrations of glucose (up to 500 mmol/l) at 37 degreesC. Minimally oxidized BSA was obtained after controlled incubations of dialyzed BSA samples with a w…

AntioxidantFree Radicalsmedicine.medical_treatmentSerum albuminBiochemistryAntioxidantsGlycationAmadori rearrangementGeneticsmedicineAnimalsHumansBovine serum albuminMolecular Biologychemistry.chemical_classificationbiologyChemistryAlbuminTryptophanSerum Albumin BovineLipoproteins LDLGlucoseBiochemistrybiology.proteinThiolCattleOxidation-ReductionBiotechnologyThe FASEB Journal
researchProduct

Antioxidant Activity of Sicilian Pistachio (Pistacia veraL. Var. Bronte) Nut Extract and Its Bioactive Components

2007

Pistacia vera L. is the only species of Pistacia genus producing edible nuts. This paper investigates the antioxidant potential of a Sicilian variety of pistachio nut by chemical as well as biological assays and measured antioxidant vitamins and a number of antioxidant polyphenols in either the hydrophilic and/or the lipophilic nut extract. In accordance with the majority of foods, the total antioxidant activity, measured as a TAA test, was much higher (50-fold) in the hydrophilic than in the lipophilic extract. Substantial amounts of total phenols were measured. The hydrophilic extract inhibited dose-dependently both the metal-dependent and -independent lipid oxidation of bovine liver micr…

Antioxidantmedicine.medical_treatmentGenisteinPISTACHIO OILAntioxidantschemistry.chemical_compoundfoodLipid oxidationmedicineAnimalsHumansFood scienceSicilyPistaciabiologyPlant ExtractsVitamin EDaidzeinfood and beveragesGeneral Chemistrybiology.organism_classificationIsoflavonesfood.foodLipoproteins LDLBiochemistrychemistryPolyphenolPistaciaMicrosomes LiverCattleLipid PeroxidationGeneral Agricultural and Biological SciencesOxidation-ReductionCopperJournal of Agricultural and Food Chemistry
researchProduct

Betanin inhibits the myeloperoxidase/nitrite-induced oxidation of human low-density lipoproteins

2007

Production of nitrogen dioxide by the activity of myeloperoxidase (MPO) in the presence of nitrite is now considered a key step in the pathophysiology of low-density lipoprotein (LDL) oxidation. This study shows that betanin, a phytochemical of the betalain class, inhibits the production of lipid hydroperoxides in human LDL submitted to a MPO/nitrite-induced oxidation. Kinetic measurements including time-course of particle oxidation and betanin consumption, either in the presence or in the absence of nitrite, suggest that the antioxidant effect is possibly the result of various actions. Betanin scavenges the initiator radical nitrogen dioxide and can also act as a lipoperoxyl radical-scaven…

Antioxidantmedicine.medical_treatmentNitrogen DioxideBiochemistrychemistry.chemical_compoundIn vivoBetalainmedicineHumansNitriteNitritesBetaninPeroxidasebiologyBetanin myeloperoxidase nitrite low-density lipoproteins atherosclerosisGeneral MedicineFree Radical ScavengersBioavailabilityLipoproteins LDLchemistryBiochemistryMyeloperoxidasebiology.proteinBetacyaninsOxidation-ReductionLipoprotein
researchProduct

ETC-1002: A future option for lipid disorders?

2014

ETC-1002 is a new investigational low density lipoprotein cholesterol (LDL-C)-lowering agent (Esperion Therapeutics, Inc.). ETC-1002 is a dicarboxylic acid derivative with a novel mechanism of action targeting two hepatic enzymes - adenosine triphosphate-citrate lyase (ACL) and adenosine monophosphate-activated protein kinase (AMPK), inhibiting sterol and fatty acid synthesis and promoting mitochondrial long-chain fatty acid oxidation. This agent is currently in phase II clinical research. Available data report that ETC-1002 significantly decreased LDL-C levels (up to 32%) in both patients with normal and elevated baseline levels of triglycerides. Such beneficial effect is superior to curre…

Apolipoprotein BLow density lipoprotein cholesterolBlood PressureAMP-Activated Protein Kinaseschemistry.chemical_compoundMiceMulticenter Studies as TopicDicarboxylic AcidsBeta oxidationHypolipidemic AgentsRandomized Controlled Trials as TopicHypolipidemic AgentbiologyFatty AcidsHyperlipidemiaTolerabilityLiverlipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicineAMP-Activated Protein Kinasemedicine.drugHumanmedicine.medical_specialtyStatinmedicine.drug_classHypercholesterolemiaHyperlipidemiasClinical Trials Phase II as TopicInternal medicinemedicineAnimalsHumansFatty acid synthesisApolipoproteins BAnimalBody WeightDicarboxylic AcidAMPKCholesterol LDLAdenosineSterolCardiometabolic riskRatsETC-1002Disease Models AnimalEndocrinologychemistrybiology.proteinATP Citrate (pro-S)-LyaseRatFatty AcidLipid lowering therapy
researchProduct

Efficacy and safety of bempedoic acid for the treatment of hypercholesterolemia: A systematic review and meta-analysis

2020

Background Bempedoic acid is a first-in-class lipid-lowering drug recommended by guidelines for the treatment of hypercholesterolemia. Our objective was to estimate its average effect on plasma lipids in humans and its safety profile. Methods and findings We carried out a systematic review and meta-analysis of phase II and III randomized controlled trials on bempedoic acid (PROSPERO: CRD42019129687). PubMed (Medline), Scopus, Google Scholar, and Web of Science databases were searched, with no language restriction, from inception to 5 August 2019. We included 10 RCTs (n = 3,788) comprising 26 arms (active arm [n = 2,460]; control arm [n = 1,328]). Effect sizes for changes in lipids and high-…

Apolipoprotein BPublication Ethics030204 cardiovascular system & hematologyCardiovascularGastroenterologyLipoprotein particleMedical and Health SciencesBiochemistrychemistry.chemical_compoundDatabase and Informatics Methods0302 clinical medicineMathematical and Statistical TechniquesAnticholesteremic Agents Apolipoproteins B Cholesterol Cholesterol LDL Clinical Trials Phase II as Topic Clinical Trials Phase III as Topic Dicarboxylic Acids Fatty Acids Humans Hypercholesterolemia Peptide Fragments Randomized Controlled Trials as TopicLipid and Blood Pressure Meta-Analysis Collaboration (LBPMC) Group and the International Lipid Expert PanelMedicine and Health SciencesDicarboxylic Acids030212 general & internal medicineDatabase SearchingResearch IntegrityRandomized Controlled Trials as Topicmedicine.diagnostic_testbiologyAnticholesteremic AgentsStatisticsFatty AcidsRDrugsGeneral MedicineMetaanalysisSerious Mental IllnessLipidsPhase III as TopicMental HealthCholesterolPhysical SciencesMedicineResearch Articlemedicine.medical_specialtyRMScience PolicyLipoproteinsHypercholesterolemiaBempedoic acid hypercholesterolemia lipid profile hsCRPResearch and Analysis MethodsLDL03 medical and health sciencesClinical Trials Phase II as TopicInternal medicineGeneral & Internal MedicinemedicineHumansClinical TrialsStatistical MethodsApolipoproteins BPharmacologyPlasma Proteinsbusiness.industryCholesterolPhase II as TopicStatinsBiology and Life SciencesProteinsOdds ratioCholesterol LDLConfidence intervalPeptide FragmentschemistryClinical Trials Phase III as Topicbiology.proteinUric acidCreatine kinaseLipid profilebusinessDigestive DiseasesMathematicsPLoS Medicine
researchProduct

Antisense lipoprotein[a] therapy: State-of-the-art and future perspectives

2020

Several lines of evidence now attest that lipoprotein[a] (Lp[a]) is a significant risk factor for many cardiovascular disorders. This enigmatic lipoprotein, composed of a single copy of apolipoprotein B (apoB) and apolipoprotein[a] (apo [a]), expresses peculiar metabolism, virtually independent from lifestyle interventions. Several therapeutic options have hence been proposed for lowering elevated Lp[a] values, with or without concomitant effect on low density lipoprotein (LDL) particles, mostly encompassing statins, ezetimibe, nicotinic acid, lipoprotein apheresis, and anti-PCSK9 monoclonal antibodies. Since all these medical treatments have some technical and clinical drawbacks, a novel s…

Apolipoprotein Bmedicine.drug_classgovernment.form_of_governmentAntisense therapyHyperlipidemias030204 cardiovascular system & hematologyPharmacologyAntisense therapy; Apolipoprotein[a]; Cardiovascular disease; Lipoprotein[a]Monoclonal antibody03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEzetimibeLipoprotein[a]Internal MedicinemedicineHumans030212 general & internal medicineAntisense therapybiologybusiness.industryLipoprotein(a)Cardiovascular diseaseLipoproteins LDLchemistryConcomitantLow-density lipoproteinBlood Component Removalbiology.proteingovernmentlipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase InhibitorsbusinessApolipoprotein[a]Lipoprotein(a)Lipoproteinmedicine.drugEuropean Journal of Internal Medicine
researchProduct